Back to companies

Coherus BioSciences Inc: Overview

Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, psoriasis arthritis and rheumatoid arthritis; and CHS-1420, is a adalimumab biosimilar candidate, which is being developed to treat crohn’s disease, ulcerative colitis, and psoriasis arthritis, UDENYCA is a pegfilgrastim biosimilar, CHS-3351 a ranibizumab biosimilar, CHS-2020 a aflibercept biosimilar and CHS-131 a Selective PPAR-gamma modulator. Coherus capabilities includes process science, analytical characterization, protein production and clinical-regulatory development. The company develops drugs in collaboration with other organizations. Coherus is headquartered in Redwood City, California, the US.

Headquarters United States of America

Address C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200, Redwood City, California, 94065


Telephone 1 650 6493530

No of Employees 368

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange CHRS (NASD)

Revenue (2021) $326.6M -31.4% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -317.1% (2021 vs 2020)

Market Cap* $524.2M

Net Profit Margin (2021) XXX -416.4% (2021 vs 2020)

* As of and is in US$

Access premium data and analytics for Coherus BioSciences Inc

30+

Clinical Trials

Determine Coherus BioSciences Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Coherus BioSciences Inc’s relevant decision makers and contact details.

16+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

12+

Pipeline Drugs

Identify which of Coherus BioSciences Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

5

Sales & Consensus Forecasts

Understand the current and future drug revenue for Coherus BioSciences Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

3

Marketed Drugs

Understand Coherus BioSciences Inc’s commercialized product portfolio to stay one step ahead of the market.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

80+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

1

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

1

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Coherus BioSciences Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline Products
Pegfilgrastim Biosimilar
Etanercept Biosimilar
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Regulatory Approval In August, the company secured approval from U.S. Food and Drug Administration (FDA) for CIMERLI (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis for all five indications, meeting the FDA’s rigorous standards to the reference product.
2022 Others In July, the company and Shanghai Junshi Biosciences Co., Ltd. announced that the United States Food and Drug Administration accepted for review the Biologics License Application resubmission for toripalimab in combination with gemcitabine and cisplatin to treat patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
2022 Financing Agreements In January, the company entered into a loan agreement with investment funds managed by Pharmakon Advisors, LP.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Coherus BioSciences Inc Moderna Inc Ligand Pharmaceuticals Inc BioCryst Pharmaceuticals Inc XOMA Corp
Headquarters United States of America United States of America United States of America United States of America United States of America
City Redwood City Cambridge San Diego Durham Emeryville
State/Province California Massachusetts California North Carolina California
No. of Employees 368 2,700 154 358 12
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Dennis M. Lanfear Chief Executive Officer; President; Chairman; Co Founder Executive Board 2010 65
McDavid Stilwell Chief Financial Officer Senior Management 2021 50
Vincent Anicetti Chief Operating Officer Senior Management 2018 66
Thomas F. Fitzpatrick Chief Legal Officer Senior Management - -
Rosh Dias, MD Chief Medical Officer Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?